Profit Margin Pressure Forces Cipla To Cut Back On Its Claim To Fame - Antiretroviral Drugs
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - In a seemingly unexpected development, Indian drug maker Cipla has decided to gradually exit from the tender-based antiretrovirals business - a move that it hopes will help in improving profit margins though volumes may dip in the short term